Orforglipron
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
Eli Lilly · Phase 4 · Not yet recruiting · Enrollment 60
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Phentermine | n/r | n/r | n/r | n/r |
| Orforglipron | n/r | n/r | n/r | n/r |
Not shown
- Phentermine: endpoint not reported
- Orforglipron: endpoint not reported